Revvity (RVTY) investor relations material

Financial performance and strategic actions

• Achieved strong quarterly results with improvements in revenue, margins, and bottom line, supported by early signs of end market recovery.

• Announced the divestiture of the China immunodiagnostics business, which represented 4.5% of revenue for the year and will improve organic growth by 100 basis points and margins by 30 basis points.

• The divestiture is expected to dilute EPS by $0.20 but will enhance free cash flow conversion and reduce working capital drag.

• Cash proceeds from the deal are estimated between $140 million and $200 million, with the transaction expected to close in the latter half of 2027.

• The decision to divest was driven by persistent pricing and volume pressures, unpredictable market conditions, and the business's limited growth prospects.

Business segment performance and outlook

• Immunodiagnostics outside China continues to perform strongly, growing high single to low double digits, with no further portfolio pruning planned.

• Pro forma organic growth excluding China immunodiagnostics was 6% in Q1, driven by extra selling days, strong reproductive health, and incremental Genomics England contract contributions.

• Life science instruments saw positive growth in both academia and pharma/biotech for the first time in three years, with high-content screening maintaining double-digit growth.

• New flagship instrument, Opera Phenix OptIQ, launched in February, expected to boost automation and sensitivity.

• Guidance assumes instrument growth slows in the second half, with overall company growth forecasted at 3%-4% for the year.

AI, software, and innovation

• AI adoption in pharma is beginning to drive demand for data-generating products like high-content screening and automation.

• Three major software launches are planned: LabGistics (June), BioDesign (May), and an AI-first workflow solution by year-end, with significant revenue impact expected from 2027.

• Software revenue is projected to grow mid-single digits for the year, with a temporary Q2 decline due to tough comps, followed by acceleration in the second half.

• The company’s Signals platform is positioned as a central tool for preclinical R&D labs, integrating AI capabilities directly into scientific workflows.

• The lab-in-a-loop concept is expected to create future demand bottlenecks for validation, benefiting automation, robotics, and consumables.